RxPG News Feed for RxPG News

Medical Research Health Special Topics World
  Home
 
   Health
 Aging
 Asian Health
 Events
 Fitness
 Food & Nutrition
 Happiness
 Men's Health
 Mental Health
 Occupational Health
 Parenting
 Public Health
 Sleep Hygiene
 Women's Health
 
   Healthcare
 Africa
 Australia
 Canada Healthcare
 China Healthcare
 India Healthcare
 New Zealand
 South Africa
 UK
 USA
 World Healthcare
 
 Latest Research
 Aging
 Alternative Medicine
 Anaethesia
 Biochemistry
 Biotechnology
 Cancer
 Cardiology
 Clinical Trials
 Cytology
 Dental
 Dermatology
 Embryology
 Endocrinology
 ENT
 Environment
 Epidemiology
 Gastroenterology
 Genetics
 Gynaecology
 Haematology
 Immunology
 Infectious Diseases
 Medicine
 Metabolism
 Microbiology
 Musculoskeletal
 Nephrology
 Neurosciences
 Obstetrics
 Ophthalmology
 Orthopedics
 Paediatrics
 Pathology
 Pharmacology
 Physiology
 Physiotherapy
 Psychiatry
 Radiology
 Rheumatology
 Sports Medicine
 Surgery
 Toxicology
 Urology
 
   Medical News
 Awards & Prizes
 Epidemics
 Launch
 Opinion
 Professionals
 
   Special Topics
 Ethics
 Euthanasia
 Evolution
 Feature
 Odd Medical News
 Climate

Last Updated: Sep 15, 2017 - 4:49:58 AM
Research Article
Latest Research Channel

subscribe to Latest Research newsletter
Latest Research

   EMAIL   |   PRINT
Trauma drama: K-State professor researches drama queen of immune system

Aug 8, 2011 - 4:00:00 AM

As a possible solution, Fleming and her lab group have developed a peptide that takes the place of the beta2 protein in binding to the molecular marker on the cell's surface, thus preventing the activation of complement.


 
[RxPG] MANHATTAN, KAN. -- Kansas State University's Sherry Fleming is investigating the factor that initiates the immune system's drama queen: the one responsible for intestinal cell damage after hemorrhage.

Fleming, an associate professor in the Division of Biology, is using a $140,000 grant from the American Heart Association to identify the molecule responsible for the overreaction that can cause cell death in the intestines after trauma.

What's starting this drama queen situation? A 13-year-old girl doesn't usually become a drama queen without a reason. There's something that initiated the drama -- clothes, shoes, make-up, movies, etc., Fleming said. With hemorrhage, we're looking for the initiating factor in the drama which occurs after trauma.

After a traumatic event, such as the loss of a limb or severe bleeding, the body cuts off blood flow to the intestines, sending more blood to the vital organs like the heart, lungs and brain, Fleming said. During that time, cells in the gut release molecular markers to let the body know that they are not getting oxygen.

After the trauma is resolved, blood flow is returned to the gut and a protein in the blood -- known as beta2 glycoprotein 1 in mice and apolipoprotein H in humans -- binds to the molecular marker on the cell to notify antibodies that there is a problem. The antibodies then activate a cascade of proteins, known as complement, that normally help the immune system by killing bacteria and helping rid tissues of dying cells. However, after a trauma this system can overreact and unnecessarily kill healthy cells.

If you've been in a car accident and sever an arm or start hemorrhaging, you want complement there to protect you from bacteria. So we don't want to stop all complement action entirely, Fleming said.

But Fleming is looking for a way to interrupt the chain of events leading to the over activation of complement following a traumatic event, because trauma patients often develop further complications throughout their body due to the activation of complement, she said.

Many times trauma patients who have lost a lot of blood will end up with acute respiratory distress syndrome or multiple organ dysfunction syndrome, due to the complement system overreacting, Fleming said. So they not only have to deal with the trauma, but also with their immune system attacking things that it shouldn't.

As a possible solution, Fleming and her lab group have developed a peptide that takes the place of the beta2 protein in binding to the molecular marker on the cell's surface, thus preventing the activation of complement.

This treatment is a promising solution, Fleming said. The funding from the American Heart Association will give us the opportunity to make major progress in this research.



Related Latest Research News


Subscribe to Latest Research Newsletter

Enter your email address:


 Feedback
For any corrections of factual information, to contact the editors or to send any medical news or health news press releases, use feedback form

Top of Page

 
Contact us

RxPG Online

Nerve

Online ACLS Certification

 

    Full Text RSS

© All rights reserved by RxPG Medical Solutions Private Limited (India)